HK Stock Market Move | H&H INTL HLDG (01112) rises over 3%; Moody's upgrades the company's rating outlook to "positive," expecting new product development to support profit growth.
H&H INTL HLDG (01112) rose over 3%. As of press time, it was up 3.4% at HK$17.95, with a turnover of HK$42.6779 million.
H&H INTL HLDG (01112) rose over 3%, up 3.4% as of press time, at HK$17.95, with a turnover of HK$42.6779 million.
On the news front, Moody's recently issued a research report stating that it has upgraded H&H INTL HLDG's rating outlook from "stable" to "positive." Moody's believes that in the first half of 2026, H&H INTL HLDG achieved a 24% year-on-year revenue increase, mainly driven by strong performance across its major business segments. Among these, infant formula milk powder sales grew 57% during the period, primarily attributable to the launch of new products and gains in market share.
Moody's expects H&H INTL HLDG to continue maintaining its strong market position and to actively develop new products and channels, which will support further profit growth over the next 12 to 18 months. Backed by its asset-light business model, the company's solid operations will help maintain positive free cash flow and continue advancing proactive debt reduction.
Related Articles
.png)
M-Grass Ecology And Environment (300355.SZ) subsidiary wins bid for a 142 million yuan restoration project.

M&A for Spectrum: Rocket Lab (RKLB.US) Sets Its Sights on Iridium Communications Inc. (IRDM.US) L-Band, CEO Says Bluntly "Spectrum Cannot Be Conjured Out of Thin Air"

Hualan Biological Engineering, Inc. (002007.SZ) announced that the marketing authorization application for Trastuzumab for Injection of its affiliated company has been accepted.
M-Grass Ecology And Environment (300355.SZ) subsidiary wins bid for a 142 million yuan restoration project.
.png)
M&A for Spectrum: Rocket Lab (RKLB.US) Sets Its Sights on Iridium Communications Inc. (IRDM.US) L-Band, CEO Says Bluntly "Spectrum Cannot Be Conjured Out of Thin Air"

Hualan Biological Engineering, Inc. (002007.SZ) announced that the marketing authorization application for Trastuzumab for Injection of its affiliated company has been accepted.






